<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801398</url>
  </required_header>
  <id_info>
    <org_study_id>EN3203-010</org_study_id>
    <nct_id>NCT00801398</nct_id>
  </id_info>
  <brief_title>Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.</brief_title>
  <official_title>An Open-Label, Ascending, Two-Part, Single- and Multiple-Dose Evaluation of the Safety, Pharmacokinetics, and Effectiveness of Oxymorphone for Acute Postoperatiave Pain in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When post-operative parenteral analgesia is discontinued, oral dosing with study medication
      may begin once the subject has developed a moderate level of pain as defined by a 100 mm VAS
      (pain intensity score greater than or equal to 40).

      This post marketing study was required by the FDA. Endo Pharmaceuticals Inc. no longer
      promotes opioids and no longer markets Opana® ER.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2009</start_date>
  <completion_date type="Actual">April 18, 2011</completion_date>
  <primary_completion_date type="Actual">April 18, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of Visual Analog Scales (VAS) of Pain Intensity Change From Baseline by Treatment Group With Single Dose of Oxymorphone IR Tablet and Multiple Dose of Oxymorphone IR Tablet</measure>
    <time_frame>Single Dose Timeframe: 15min, 30min, 1h, 2h, 3h, 4h, 6h or Rescue; Multiple Dose Timeframe: 15min, 30min, 1h, 2h, 3h, 4h, 6h, subsequent doses every 4-6 hours (Multiple Dose #1-11), and Early Termination</time_frame>
    <description>Change from Baseline in 100-mm Visual Analog Scales (VAS) in Multiple Dose of Oxymorphone IR Tablet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects Taking Rescue Medication</measure>
    <time_frame>first dose through 48 hours after first dose</time_frame>
    <description>Percentages are based on the number of subjects in each treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) of Single Dose of Oxymorphone by Treatment Group</measure>
    <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
    <description>AUC0-t: Area under the concentration versus time curve from time 0 to the last measured concentration (Ct), calculated by linear trapezoidal rule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf) of Single Dose of Oxymorphone by Treatment Group</measure>
    <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
    <description>AUC0-inf: Area under the concentration versus time curve from time 0 to infinity, calculated as AUC0-t + Ct/terminal rate constant (single-dose period only), where Ct is the concentration at the time of the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Single Dose of Oxymorphone by Treatment Group</measure>
    <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
    <description>Cmax: Maximum plasma concentration; the highest concentration observed during a dosage interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Single Dose of Oxymorphone by Treatment Group</measure>
    <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
    <description>Tmax: The time at which Cmax was observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant of Single Dose of Oxymorphone by Treatment Group</measure>
    <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
    <description>λ: Terminal rate constant, calculated as the negative slope of the ln-linear portion of the terminal plasma concentration-time curve (single-dose period only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life of Single Dose of Oxymorphone by Treatment Group</measure>
    <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
    <description>t½: Terminal half-life, calculated as terminal rate constant/(ln 2) (single-dose period only)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Oxymorphone IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-Label, 2 part ascending-dose multicenter study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymorphone IR</intervention_name>
    <description>Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs</description>
    <arm_group_label>Oxymorphone IR</arm_group_label>
    <other_name>Opana IR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt; 12 to 17 years of age, inclusive

          -  Weigh at least 50 kg

          -  Postoperative oral opioid analgesia required for at least 24 hours or 48 hours
             following postoperataive parenteral analgesia

          -  Are expected to be hospitalized for the duration of the study

        Exclusion Criteria:

          -  Known allergy to, or a significant reaction to, oxymorphone or another opioid

          -  Life expectancy of &lt; 4 weeks

          -  Positive pregnancy test at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Children's Hospital of Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Carell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <results_first_submitted>December 20, 2018</results_first_submitted>
  <results_first_submitted_qc>February 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2019</results_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid tolerant</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Pain</keyword>
  <keyword>Non malignant</keyword>
  <keyword>Malignant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxymorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Dose of Oxymorphone IR: 5mg Tablet</title>
        </group>
        <group group_id="P2">
          <title>Single Dose of Oxymorphone IR: 10mg Tablet</title>
        </group>
        <group group_id="P3">
          <title>Single Dose of Oxymorphone IR: 15mg Tablet</title>
        </group>
        <group group_id="P4">
          <title>Multiple Dose of Oxymorphone: 5mg Tablet</title>
        </group>
        <group group_id="P5">
          <title>Multiple Dose of Oxymorphone IR: 10mg Tablet</title>
        </group>
        <group group_id="P6">
          <title>Multiple Dose of Oxymorphone IR: 15mg Tablet</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population; Single Dose Total = 33; Multiple Dose Total = 25;</population>
      <group_list>
        <group group_id="B1">
          <title>Single Dose of Oxymorphone IR: 5mg Tablet</title>
        </group>
        <group group_id="B2">
          <title>Single Dose of Oxymorphone IR: 10mg Tablet</title>
        </group>
        <group group_id="B3">
          <title>Single Dose of Oxymorphone IR: 15mg Tablet</title>
        </group>
        <group group_id="B4">
          <title>Multiple Dose of Oxymorphone IR: 5mg Tablet</title>
        </group>
        <group group_id="B5">
          <title>Multiple Dose of Oxymorphone IR: 10mg Tablet</title>
        </group>
        <group group_id="B6">
          <title>Multiple Dose of Oxymorphone IR: 15mg Tablet</title>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Single Dose of Oxymorphone IR Overall (N=33): Mean 14.9 SD (1.64) Multiple Dose of Oxymorphone IR Overall (N=25): Mean 15.2 SD (1.13)</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.9" spread="1.71"/>
                    <measurement group_id="B2" value="15.3" spread="1.66"/>
                    <measurement group_id="B3" value="14.6" spread="1.63"/>
                    <measurement group_id="B4" value="15.0" spread="0.71"/>
                    <measurement group_id="B5" value="15.3" spread="1.58"/>
                    <measurement group_id="B6" value="15.5" spread="1.07"/>
                    <measurement group_id="B7" value="15.07" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Visual Analog Scales (VAS) of Pain Intensity Change From Baseline by Treatment Group With Single Dose of Oxymorphone IR Tablet and Multiple Dose of Oxymorphone IR Tablet</title>
        <description>Change from Baseline in 100-mm Visual Analog Scales (VAS) in Multiple Dose of Oxymorphone IR Tablet</description>
        <time_frame>Single Dose Timeframe: 15min, 30min, 1h, 2h, 3h, 4h, 6h or Rescue; Multiple Dose Timeframe: 15min, 30min, 1h, 2h, 3h, 4h, 6h, subsequent doses every 4-6 hours (Multiple Dose #1-11), and Early Termination</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Change From Baseline Single Dose of Oxymorphone IR: 5mg Tablet</title>
            <description>Change from Baseline</description>
          </group>
          <group group_id="O2">
            <title>Change From Baseline Single Dose Oxymorphone IR: 10mg Tablet</title>
            <description>Change from Baseline</description>
          </group>
          <group group_id="O3">
            <title>Change From Baseline Single Dose Oxymorphone IR: 15mg Tablet</title>
            <description>Change from Baseline</description>
          </group>
          <group group_id="O4">
            <title>Change From Baseline Multiple Dose Oxymorphone IR: 5mg Tablet</title>
            <description>Change from Baseline</description>
          </group>
          <group group_id="O5">
            <title>Change From Baseline Multiple Dose Oxymorphone IR: 10mg Tablet</title>
            <description>Change from Baseline</description>
          </group>
          <group group_id="O6">
            <title>Change From Baseline Multiple Dose Oxymorphone IR: 15mg Tablet</title>
            <description>Change from Baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Visual Analog Scales (VAS) of Pain Intensity Change From Baseline by Treatment Group With Single Dose of Oxymorphone IR Tablet and Multiple Dose of Oxymorphone IR Tablet</title>
          <description>Change from Baseline in 100-mm Visual Analog Scales (VAS) in Multiple Dose of Oxymorphone IR Tablet</description>
          <population>ITT Population</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 Minutes Post Dose/ 15 Minutes Post First Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="22.86"/>
                    <measurement group_id="O2" value="-22.2" spread="17.79"/>
                    <measurement group_id="O3" value="-21.6" spread="13.59"/>
                    <measurement group_id="O4" value="-16.7" spread="23.31"/>
                    <measurement group_id="O5" value="0.5" spread="9.56"/>
                    <measurement group_id="O6" value="-17.4" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Minutes Post Dose/30 Minutes Post First Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="36.90"/>
                    <measurement group_id="O2" value="-13.7" spread="28.32"/>
                    <measurement group_id="O3" value="-22.9" spread="19.87"/>
                    <measurement group_id="O4" value="-18.3" spread="25.84"/>
                    <measurement group_id="O5" value="3.1" spread="22.33"/>
                    <measurement group_id="O6" value="-23.0" spread="15.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hour Post Dose/1 Hour Post First Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.70" spread="36.74"/>
                    <measurement group_id="O2" value="-17.4" spread="28.64"/>
                    <measurement group_id="O3" value="-29.8" spread="20.02"/>
                    <measurement group_id="O4" value="-22.0" spread="25.13"/>
                    <measurement group_id="O5" value="-7.8" spread="18.90"/>
                    <measurement group_id="O6" value="-28.3" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hours Post Dose/2 Hours Post First Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.3" spread="29.07"/>
                    <measurement group_id="O2" value="-29.0" spread="25.55"/>
                    <measurement group_id="O3" value="-33.8" spread="20.10"/>
                    <measurement group_id="O4" value="-14.4" spread="36.56"/>
                    <measurement group_id="O5" value="-6.3" spread="22.04"/>
                    <measurement group_id="O6" value="-12.9" spread="34.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Hours Post Dose/3 Hours Post First Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.4" spread="26.97"/>
                    <measurement group_id="O2" value="-29.3" spread="20.21"/>
                    <measurement group_id="O3" value="-28.6" spread="16.75"/>
                    <measurement group_id="O4" value="-25.8" spread="40.17"/>
                    <measurement group_id="O5" value="-15.5" spread="19.67"/>
                    <measurement group_id="O6" value="-24.7" spread="20.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours Post Dose/4 Hours Post First Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.2" spread="25.03"/>
                    <measurement group_id="O2" value="-19.5" spread="45.96"/>
                    <measurement group_id="O3" value="-31.5" spread="14.20"/>
                    <measurement group_id="O4" value="-34.8" spread="31.65"/>
                    <measurement group_id="O5" value="-7.5" spread="29.33"/>
                    <measurement group_id="O6" value="-10.8" spread="20.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Hrs Post Dose or Rescue/6 Hours Post First Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.4" spread="25.32"/>
                    <measurement group_id="O2" value="-3.0" spread="21.85"/>
                    <measurement group_id="O3" value="-18.2" spread="18.73"/>
                    <measurement group_id="O4" value="-41.0" spread="NA">SD cannot be derived based on one subject data point</measurement>
                    <measurement group_id="O5" value="-6.0" spread="20.22"/>
                    <measurement group_id="O6" value="-38.3" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-28.0" spread="14.11"/>
                    <measurement group_id="O5" value="-15.0" spread="17.72"/>
                    <measurement group_id="O6" value="-25.2" spread="11.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-33.5" spread="10.61"/>
                    <measurement group_id="O5" value="0.8" spread="7.04"/>
                    <measurement group_id="O6" value="-17.6" spread="20.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-33.5" spread="10.61"/>
                    <measurement group_id="O5" value="4.0" spread="18.38"/>
                    <measurement group_id="O6" value="-26.4" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-33.0" spread="11.31"/>
                    <measurement group_id="O5" value="18.5" spread="13.44"/>
                    <measurement group_id="O6" value="-25.4" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-38.0" spread="4.24"/>
                    <measurement group_id="O5" value="-19.0" spread="41.01"/>
                    <measurement group_id="O6" value="-21.6" spread="19.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-38.0" spread="4.24"/>
                    <measurement group_id="O5" value="-1.0" spread="NA">SD cannot be derived based on one subject data point</measurement>
                    <measurement group_id="O6" value="-32.8" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-33.0" spread="NA">SD cannot be derived based on one subject data point</measurement>
                    <measurement group_id="O5" value="-36.0" spread="NA">SD cannot be derived based on one subject data point</measurement>
                    <measurement group_id="O6" value="-26.6" spread="21.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-35.0" spread="NA">SD cannot be derived based on one subject data point</measurement>
                    <measurement group_id="O5" value="-8.0" spread="NA">SD cannot be derived based on one subject data point</measurement>
                    <measurement group_id="O6" value="-32.7" spread="13.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-34.0" spread="NA">SD cannot be derived based on one subject data point</measurement>
                    <measurement group_id="O5" value="-6.0" spread="NA">SD cannot be derived based on one subject data point</measurement>
                    <measurement group_id="O6" value="-22.7" spread="15.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-6.0"/>
                    <measurement group_id="O6" value="-29.0" spread="17.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose #11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-29.0" spread="NA">SD cannot be derived based on one subject data point</measurement>
                    <measurement group_id="O6" value="-17.0" spread="NA">SD cannot be derived based on one subject data point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1.8" spread="50.74"/>
                    <measurement group_id="O5" value="7.4" spread="42.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjects Taking Rescue Medication</title>
        <description>Percentages are based on the number of subjects in each treatment group.</description>
        <time_frame>first dose through 48 hours after first dose</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Oxymorphone IR: 5mg Tablet</title>
            <description>Subjects With at Least One Rescue Medication</description>
          </group>
          <group group_id="O2">
            <title>Single Dose of Oxymorphone IR: 10mg Tablet</title>
            <description>Subjects With at Least One Rescue Medication</description>
          </group>
          <group group_id="O3">
            <title>Single Dose of Oxymorphone IR: 15mg Tablet</title>
            <description>Subjects With at Least One Rescue Medication</description>
          </group>
          <group group_id="O4">
            <title>Multiple Dose of Oxymorphone: 5mg Tablet</title>
            <description>Subjects With at Least One Rescue Medication</description>
          </group>
          <group group_id="O5">
            <title>Multiple Dose of Oxymorphone IR: 10mg Tablet</title>
            <description>Subjects With at Least One Rescue Medication</description>
          </group>
          <group group_id="O6">
            <title>Multiple Dose of Oxymorphone IR: 15mg Tablet</title>
            <description>Subjects With at Least One Rescue Medication</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Taking Rescue Medication</title>
          <description>Percentages are based on the number of subjects in each treatment group.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-t) of Single Dose of Oxymorphone by Treatment Group</title>
        <description>AUC0-t: Area under the concentration versus time curve from time 0 to the last measured concentration (Ct), calculated by linear trapezoidal rule</description>
        <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
        <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Oxymorphone IR: 5mg Tablet</title>
          </group>
          <group group_id="O2">
            <title>Single Dose of Oxymorphone IR: 10mg Tablet</title>
          </group>
          <group group_id="O3">
            <title>Single Dose of Oxymorphone IR: 15mg Tablet</title>
          </group>
          <group group_id="O4">
            <title>Single Dose of 6-OH-Oxymorphone: 5mg Tablet</title>
          </group>
          <group group_id="O5">
            <title>6-OH-Oxymorphone (ng/mL): 10mg</title>
          </group>
          <group group_id="O6">
            <title>6-OH-Oxymorphone (ng/mL): 15mg</title>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) of Single Dose of Oxymorphone by Treatment Group</title>
          <description>AUC0-t: Area under the concentration versus time curve from time 0 to the last measured concentration (Ct), calculated by linear trapezoidal rule</description>
          <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.395" spread="6.0752"/>
                    <measurement group_id="O2" value="3.766" spread="2.2587"/>
                    <measurement group_id="O3" value="67.040" spread="150.7979"/>
                    <measurement group_id="O4" value="1.544" spread="1.8794"/>
                    <measurement group_id="O5" value="3.040" spread="1.1625"/>
                    <measurement group_id="O6" value="7.354" spread="3.3255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-inf) of Single Dose of Oxymorphone by Treatment Group</title>
        <description>AUC0-inf: Area under the concentration versus time curve from time 0 to infinity, calculated as AUC0-t + Ct/terminal rate constant (single-dose period only), where Ct is the concentration at the time of the last quantifiable concentration</description>
        <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
        <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Oxymorphone IR: 5mg Tablet</title>
          </group>
          <group group_id="O2">
            <title>Single Dose of Oxymorphone IR: 10mg Tablet</title>
          </group>
          <group group_id="O3">
            <title>Single Dose of Oxymorphone IR: 15mg Tablet</title>
          </group>
          <group group_id="O4">
            <title>Single Dose of 6-OH-Oxymorphone: 5mg Tablet</title>
          </group>
          <group group_id="O5">
            <title>Single Dose of 6-OH-Oxymorphone: 10mg Tablet</title>
          </group>
          <group group_id="O6">
            <title>Single Dose 6-OH-Oxymorphone: 15mg Tablet</title>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf) of Single Dose of Oxymorphone by Treatment Group</title>
          <description>AUC0-inf: Area under the concentration versus time curve from time 0 to infinity, calculated as AUC0-t + Ct/terminal rate constant (single-dose period only), where Ct is the concentration at the time of the last quantifiable concentration</description>
          <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.632" spread="6.6828"/>
                    <measurement group_id="O2" value="10.223" spread="6.5195"/>
                    <measurement group_id="O3" value="109.294" spread="257.5421"/>
                    <measurement group_id="O4" value="4.987" spread="7.5732"/>
                    <measurement group_id="O5" value="8.692" spread="10.2430"/>
                    <measurement group_id="O6" value="12.795" spread="8.8385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Single Dose of Oxymorphone by Treatment Group</title>
        <description>Cmax: Maximum plasma concentration; the highest concentration observed during a dosage interval</description>
        <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
        <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Oxymorphone IR: 5mg Tablet</title>
          </group>
          <group group_id="O2">
            <title>Single Dose of Oxymorphone IR: 10mg Tablet</title>
          </group>
          <group group_id="O3">
            <title>Single Dose of Oxymorphone IR: 15mg Tablet</title>
          </group>
          <group group_id="O4">
            <title>Single Dose of 6-OH-Oxymorphone: 5mg Tablet</title>
          </group>
          <group group_id="O5">
            <title>Single Dose of 6-OH-Oxymorphone: 10mg Tablet</title>
          </group>
          <group group_id="O6">
            <title>Single Dose 6-OH-Oxymorphone: 15mg Tablet</title>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Single Dose of Oxymorphone by Treatment Group</title>
          <description>Cmax: Maximum plasma concentration; the highest concentration observed during a dosage interval</description>
          <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.243" spread="1.2192"/>
                    <measurement group_id="O2" value="0.828" spread="0.6892"/>
                    <measurement group_id="O3" value="5.295" spread="10.6386"/>
                    <measurement group_id="O4" value="0.314" spread="0.3276"/>
                    <measurement group_id="O5" value="0.487" spread="0.2853"/>
                    <measurement group_id="O6" value="0.940" spread="0.5212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Single Dose of Oxymorphone by Treatment Group</title>
        <description>Tmax: The time at which Cmax was observed</description>
        <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
        <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Oxymorphone IR: 5mg Tablet</title>
          </group>
          <group group_id="O2">
            <title>Single Dose of Oxymorphone IR: 10mg Tablet</title>
          </group>
          <group group_id="O3">
            <title>Single Dose of Oxymorphone IR: 15mg Tablet</title>
          </group>
          <group group_id="O4">
            <title>Single Dose of 6-OH-Oxymorphone: 5mg Tablet</title>
          </group>
          <group group_id="O5">
            <title>Single Dose of 6-OH-Oxymorphone: 10mg Tablet</title>
          </group>
          <group group_id="O6">
            <title>Single Dose 6-OH-Oxymorphone: 15mg Tablet</title>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Single Dose of Oxymorphone by Treatment Group</title>
          <description>Tmax: The time at which Cmax was observed</description>
          <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.898" spread="3.9645"/>
                    <measurement group_id="O2" value="3.681" spread="2.4102"/>
                    <measurement group_id="O3" value="6.193" spread="6.3784"/>
                    <measurement group_id="O4" value="3.885" spread="2.7228"/>
                    <measurement group_id="O5" value="4.631" spread="3.7051"/>
                    <measurement group_id="O6" value="3.785" spread="3.2552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Rate Constant of Single Dose of Oxymorphone by Treatment Group</title>
        <description>λ: Terminal rate constant, calculated as the negative slope of the ln-linear portion of the terminal plasma concentration-time curve (single-dose period only)</description>
        <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
        <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Oxymorphone IR: 5mg Tablet</title>
          </group>
          <group group_id="O2">
            <title>Single Dose of Oxymorphone IR: 10mg Tablet</title>
          </group>
          <group group_id="O3">
            <title>Single Dose of Oxymorphone IR: 15mg Tablet</title>
          </group>
          <group group_id="O4">
            <title>Single Dose of 6-OH-Oxymorphone: 5mg Tablet</title>
          </group>
          <group group_id="O5">
            <title>Single Dose of 6-OH-Oxymorphone: 10mg Tablet</title>
          </group>
          <group group_id="O6">
            <title>Single Dose 6-OH-Oxymorphone: 15mg Tablet</title>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant of Single Dose of Oxymorphone by Treatment Group</title>
          <description>λ: Terminal rate constant, calculated as the negative slope of the ln-linear portion of the terminal plasma concentration-time curve (single-dose period only)</description>
          <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
          <units>Time -1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.209" spread="0.2552"/>
                    <measurement group_id="O2" value="0.214" spread="0.2962"/>
                    <measurement group_id="O3" value="0.073" spread="0.0549"/>
                    <measurement group_id="O4" value="0.281" spread="0.2072"/>
                    <measurement group_id="O5" value="0.101" spread="0.0965"/>
                    <measurement group_id="O6" value="0.042" spread="0.0234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life of Single Dose of Oxymorphone by Treatment Group</title>
        <description>t½: Terminal half-life, calculated as terminal rate constant/(ln 2) (single-dose period only)</description>
        <time_frame>Baseline, 2h, 4h, 8h, 12h, 24h, 28h, 32h, 36h and 48h</time_frame>
        <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose of Oxymorphone IR: 5mg Tablet</title>
          </group>
          <group group_id="O2">
            <title>Single Dose of Oxymorphone IR: 10mg Tablet</title>
          </group>
          <group group_id="O3">
            <title>Single Dose of Oxymorphone IR: 15mg Tablet</title>
          </group>
          <group group_id="O4">
            <title>Single Dose of 6-OH-Oxymorphone: 5mg Tablet</title>
          </group>
          <group group_id="O5">
            <title>Single Dose of 6-OH-Oxymorphone: 10mg Tablet</title>
          </group>
          <group group_id="O6">
            <title>Single Dose 6-OH-Oxymorphone: 15mg Tablet</title>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life of Single Dose of Oxymorphone by Treatment Group</title>
          <description>t½: Terminal half-life, calculated as terminal rate constant/(ln 2) (single-dose period only)</description>
          <population>PK Population (only including subjects with sufficient evaluable time points for this outcome measure).</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.099" spread="9.9336"/>
                    <measurement group_id="O2" value="15.900" spread="18.2533"/>
                    <measurement group_id="O3" value="19.974" spread="22.4488"/>
                    <measurement group_id="O4" value="19.215" spread="37.3737"/>
                    <measurement group_id="O5" value="23.635" spread="33.6381"/>
                    <measurement group_id="O6" value="22.520" spread="15.3063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs (Single Dose and Multiple Dose) were collected by the investigator starting 15 minutes after the first dose through the end of the study evaluation (24 hours post-first dose or early termination for Single Dose and 48 hours post first dose or early termination for Multiple Dose) and for up to 30 days after the last dose of study medication; this included any AEs that were ongoing at the completion/termination of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Dose of Oxymorphone IR: 5mg Tablet</title>
        </group>
        <group group_id="E2">
          <title>Single Dose of Oxymorphone IR: 10mg Tablet</title>
        </group>
        <group group_id="E3">
          <title>Single Dose of Oxymorphone IR: 15mg Tablet</title>
        </group>
        <group group_id="E4">
          <title>Multiple Dose of Oxymorphone IR: 5mg Tablet</title>
        </group>
        <group group_id="E5">
          <title>Multiple Dose of Oxymorphone IR: 10mg Tablet</title>
        </group>
        <group group_id="E6">
          <title>Multiple Dose of Oxymorphone IR: 15mg Tablet</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, Version 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Pupils unequal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fat embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Failure of implant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Somatosensory evoked</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Spinal cord oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, Version 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This post marketing study was required by the FDA. Endo Pharmaceuticals Inc. no longer promotes opioids and no longer markets Opana® ER.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Saji Vijayan</name_or_title>
      <organization>Endo Pharmaceuticals</organization>
      <phone>(800) 462-3636</phone>
      <email>ClinicalTrials@Endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

